Pacira BioSciences (PCRX) Income towards Parent Company (2010 - 2026)

Pacira BioSciences' Income towards Parent Company history runs 17 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 39.4% year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $5.1 million, a 104.95% increase from a year earlier, with the FY2025 full-year figure at $7.0 million, up 107.07% from the prior year.
• Income towards Parent Company advanced to $2.9 million in Q1 2026 per PCRX's latest filing, from $1.6 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $25.8 million in Q2 2023 and bottomed at -$143.5 million in Q3 2024.
• The 5-year median for Income towards Parent Company is $5.4 million (2025), against an average of -$1.9 million.
• Across the five-year window, Income towards Parent Company surged 1666.81% in 2023 and slumped 1421.29% in 2024, its largest moves.
• Year by year, Income towards Parent Company stood at -$10.1 million in 2022, then soared by 346.19% to $24.9 million in 2023, then slumped by 35.5% to $16.0 million in 2024, then plunged by 89.79% to $1.6 million in 2025, then soared by 78.13% to $2.9 million in 2026.
• Per Business Quant, the three latest PCRX Income towards Parent Company figures stand at $2.9 million (Q1 2026), $1.6 million (Q4 2025), and $5.4 million (Q3 2025).